Iovance Achieves 52% Early-Line and 44% Overall Response Rates in Amtagvi Trial
Iovance Biotherapeutics unveiled Amtagvi trial results showing a 44% overall response rate and a 52% response rate in patients treated after two or fewer prior therapies. Five-year durability and survival data further support its best-in-class profile for advanced melanoma treatment.
1. Trial Data Demonstrate High Response Rates
Iovance presented trial results demonstrating a 44% overall response rate in advanced melanoma patients and a 52% response rate in those treated after two or fewer prior therapies.
2. Durability and Survival Data Reinforce Profile
Five-year durability and survival metrics were highlighted, underscoring the therapy’s sustained clinical benefit and supporting its positioning as a best-in-class tumor-infiltrating lymphocyte treatment.
3. Potential Market Impact Addresses Unmet Need
With over 8,000 annual deaths from advanced melanoma in the US, these results position Iovance to address a significant unmet medical need and potentially drive commercial uptake of Amtagvi.